Saying that a paper has “fatal and disqualifying errors,” CrossFit is demanding the retraction of a recently published article that claimed those participating in CrossFit “are more likely to be injured and to seek medical treatment compared with participants in traditional weightlifting.”
A former researcher at Boston University (BU) committed research misconduct, according to the U.S. Office of Research Integrity (ORI).
William W. Cruikshank, formerly of BU’s Pulmonary Center, “engaged in research misconduct by knowingly, intentionally, and/or recklessly falsifying and/or fabricating data” in a paper retracted in 2014, in an earlier version of that paper, in a seminar presentation, and in two grant applications submitted to the National Cancer Institute, the ORI reports.
Cruikshank did so by “copying blot band images from unrelated sources, manipulating to disguise their origin, and combining multiple images to generate new figures to falsely represent results using sixty-four (64) such band images” in 16 figures and related text.
Last year, amid concerns for patient safety, the U.S. National Institutes of Health (NIH) suspended seven grants to Duke University following “allegations of research misconduct…and…potential issues concerning clinical research irregularities,” we now know thanks to a letter from NIH to Duke.
On March 30, 2018, The Ohio State University (OSU) released a 75-page report concluding that Ching-Shih Chen, a cancer researcher, had deviated “from the accepted practices of image handling and figure generation and intentionally falsifying data.” The report recommended the retraction of eight papers.
By the end of August of 2018, Chen had had four papers retracted — one in Cancer Research, two in the Journal of Medicinal Chemistry, and one in PLoS ONE.
But it wasn’t until more than a year after the report was released that the other four papers — two from Carcinogenesis, one from Clinical Cancer Research, and one from Molecular Cellular Therapeutics — were retracted, all between April 1 and May 1 of this year.
What took so long? Your guess is as good as ours; none of the editors of those journals responded to our requests for comment.
Retraction Watch readers may have noticed what seems like a growing trend: Co-first authorships. While the move might seem like a way to promote equality, some researchers are worried that it’s having the opposite effect. In response, the Journal of Clinical Investigation (JCI) recently created additional requirements for shared first authorship. We asked Arturo Casadevall, the first author of an editorial describing those changes, to answer a few questions.
Retraction Watch (RW): The title of your editorial, as well as the editorial itself, refers to bias. What kind of bias is of concern when it comes to co-first authors?